Bank of New York Mellon
ONC

Bank of New York Mellon’s BeOne Medicines Ltd ONC Stock Holding History

Bank of New York Mellon’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$805K Sell
2,824
-1,808
-39% -$533K ﹤0.01% 3485
2026
Q1 		$1.38M Buy
4,632
+1,855
+67% +$600K ﹤0.01% 3018
2025
Q4 		$844K Buy
2,777
+4
+0.1% +$1.31K ﹤0.01% 3335
2025
Q3 		$945K Hold
2,773
– – ﹤0.01% 3242
2025
Q2 		$671K Sell
2,773
-3
-0.1% -$736 ﹤0.01% 3348
2025
Q1 		$756K Sell
2,776
-133
-5% -$31.1K ﹤0.01% 3212
2024
Q4 		$537K Sell
2,909
-175
-6% -$35.8K ﹤0.01% 3487
2024
Q3 		$692K Sell
3,084
-2,215
-42% -$399K ﹤0.01% 3340
2024
Q2 		$756K Sell
5,299
-99
-2% -$15.3K ﹤0.01% 3341
2024
Q1 		$844K Buy
5,398
+2,177
+68% +$351K ﹤0.01% 3242
2023
Q4 		$581K Sell
3,221
-975
-23% -$176K ﹤0.01% 3471
2023
Q3 		$755K Sell
4,196
-2,110
-33% -$418K ﹤0.01% 3336
2023
Q2 		$1.12M Sell
6,306
-477
-7% -$110K ﹤0.01% 3128
2023
Q1 		$1.46M Sell
6,783
-387
-5% -$92.8K ﹤0.01% 2966
2022
Q4 		$1.58M Sell
7,170
-50,669
-88% -$9.29M ﹤0.01% 2970
2022
Q3 		$7.8M Buy
57,839
+1,348
+2% +$231K ﹤0.01% 2046
2022
Q2 		$9.14M Buy
56,491
+1,292
+2% +$202K ﹤0.01% 1988
2022
Q1 		$10.4M Buy
55,199
+308
+0.6% +$65.5K ﹤0.01% 2048
2021
Q4 		$14.9M Sell
54,891
-4
-0% -$1.35K ﹤0.01% 1891
2021
Q3 		$19.9M Buy
54,895
+5,387
+11% +$1.76M ﹤0.01% 1728
2021
Q2 		$17M Sell
49,508
-7,548
-13% -$2.5M ﹤0.01% 1825
2021
Q1 		$19.9M Sell
57,056
-907
-2% -$300K ﹤0.01% 1710
2020
Q4 		$15M Sell
57,963
-19,237
-25% -$5.3M ﹤0.01% 1790
2020
Q3 		$22.1M Buy
77,200
+1,466
+2% +$345K 0.01% 1404
2020
Q2 		$14.3M Buy
75,734
+8,708
+13% +$1.42M ﹤0.01% 1641
2020
Q1 		$8.25M Buy
67,026
+2,623
+4% +$410K ﹤0.01% 1805
2019
Q4 		$10.7M Sell
64,403
-2,250
-3% -$374K ﹤0.01% 1938
2019
Q3 		$8.16M Buy
66,653
+1,751
+3% +$233K ﹤0.01% 2029
2019
Q2 		$8.04M Buy
64,902
+4,271
+7% +$542K ﹤0.01% 2085
2019
Q1 		$8M Buy
60,631
+1,873
+3% +$253K ﹤0.01% 2084
2018
Q4 		$8.24M Buy
+58,758
New +$7.79M ﹤0.01% 2016

Other funds holding ONC

Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Baird Financial Group
Baird Financial Group Milwaukee, Wisconsin $72.7B AUM 26.4% 1-Year Est. Return
CII
Capital International Inc Los Angeles, California $14.3B AUM 34.19% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Bank of New York Mellon's ONC Position: Q2 2026 in Review

Bank of New York Mellon reduced its BeOne Medicines Ltd (ONC) stake by 39% in Q2 2026, selling an estimated $533K and leaving 2,824 shares worth $805K. The position accounts for ﹤0.01% of the portfolio, ranked #3485.

Bank of New York Mellon first reported a position in ONC in Q4 2018 and has held it in 31 quarters since. The position peaked at $22.1M in Q3 2020. 219 funds tracked by Wall St. Rank hold ONC as of Q2 2026.

  • Bank of New York Mellon held 2,824 shares of BeOne Medicines Ltd worth $805K as of Q2 2026.
  • Bank of New York Mellon sold 1,808 BeOne Medicines Ltd shares in Q2 2026, an estimated $533K.
  • BeOne Medicines Ltd made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3485 holding.
  • Bank of New York Mellon first reported a position in BeOne Medicines Ltd in Q4 2018 and has held it in 31 quarters since.
  • Bank of New York Mellon's BeOne Medicines Ltd position peaked at $22.1M in Q3 2020.
  • 219 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.